InVivo offers a recombinant form of the peptidase domain (PD) of Angiotensin-converting enzyme 2 (ACE2), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells). ACE2 is the cellular receptor for severe acute respiratory syndrome–coronavirus (SARS-CoV-2). The receptor-binding domain (RBD) of the SARS-CoV-2 Spike (S) protein interacts with the peptidase domain (PD, residues 19–615) of ACE2.
The construct contains residues 1–615 of ACE2, comprising the native signal peptide and the peptidase domain (PD). The mature protein is predicted to start with Gln18. The protein includes a C-terminal hexa-histidine-tag and is purified using immobilized metal exchange chromatography (IMAC).
| Product-ID: |
RP_SZ_819 |
| Expression System: |
Mammalian; HEK |
| Protein Acession Number: |
UniProt: Q9BYF1 |
| Amino Acids: |
Met1–Asp615 (including signal peptide) |
| Mature Protein N-Term: |
Gln18 (predicted) |
| Tag: |
6 x His-Tag; C-terminal |
| Expected Molecular Weight: |
70.0 kDa (monomeric) |
| Formulation: |
Liquid ; 20 mM NaPP, 300 mM NaCl pH 7.2 |
| Concentration: |
> 0.5 mg/ mL |
| Purity: |
> 90% (via analytical CGE under reducing conditions) |
| Specific Activity: |
≥ 1 μmol/min/mg enzyme |
The product is for research use or for further manufacturing only.
Reviews
There are no reviews yet.